References
- Matuk-Villazon O, Roberts JC, Corrales-Medina FF, Hemophilia: The
Past, the Present, and the Future, Pediatr Rev. 2021 Dec
1;42(12):672-683.
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the
management of hemophilia, 3rd edition. Haemophilia.2020;26(Suppl 6):1–158.
- Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as
factor VIII replacement therapy for hemophilia A. N Engl J Med
2020;383:1018-1027.
- Bioverativ Therapeutics Inc. Efanesoctocog alfa [antihemophilic
factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl]: US
prescribing information. 2023.
- Malec L, Peyvandi F, Chan AKC, et al; for the XTEND-Kids Trial Group.
Efanesoctocog alfa prophylaxis for previously treated patients
<12 years of age with severe hemophilia A. ISTH 2023
Congress; June 24-28, 2023. Abstract LB01.1.
- Pipe S, Sadeghi‐Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M,
Santagostino E, Willemze A, Abad‐Franch L, Knobe K, Seth Chhabra E. A
global comparative field study to evaluate the factor VIII activity of
efanesoctocog alfa by one‐stage clotting and chromogenic substrate
assays at clinical haemostasis laboratories. Haemophilia. 2023 Oct
30. doi: 10.1111/hae.14831. Online ahead of print.